Adverum Biotechnologies

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Responds to Intent to Nominate Directors from Sonic Fund

Adverum Announces Board Slate for 2021 Annual Meeting and Reiterates Commitment to Stockholder Value Creation

Investors need to pay close attention to Adverum Biotechnologies (ADVM) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Adverum Biotechnologies (ADVM) Stock?

Adverum Biotechnologies, Inc's (ADVM) CEO Laurent Fischer on Q4 2020 Results - Earnings Call Transcript

Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of -21.88% and -100.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Adverum Biotechnologies (ADVM) Reports Q4 Loss, Misses Revenue Estimates

-- BLA submission targeted in 2024 -- -- Alignment on clinical development and CMC requirements from recent interactions with FDA --

Adverum Announces Shortened Timelines and Clear Development Path for ADVM-022 Intravitreal Gene Therapy in Wet AMD, Reports Recent Business Progress and Fourth Quarter 2020 Financial Results

Key Opinion Leader Arshad M. Khanani, M.D., M.A., director of clinical research, Sierra Eye Associates, and OPTIC and INFINITY trial investigator will participate on this call Key Opinion Leader Arshad M. Khanani, M.D., M.A., director of clinical research, Sierra Eye Associates, and OPTIC and INFINITY trial investigator will participate on this call

Adverum to Host Conference Call and Webcast to Highlight Updated ADVM-022 Development Plans in Wet AMD, Recent Business Progress, and Fourth Quarter 2020 Financial Results

REDWOOD CITY, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Reed V. Tuckson, M.D., FACP as an independent member of Adverum's Board of Directors. Dr. Tuckson brings extensive policy knowledge from his experience in multiple facets of the healthcare industry, including a 13-year tenure in senior leadership positions at UnitedHealth Group, where he served as chief of medical affairs.

Adverum Appoints Esteemed Healthcare Executive Reed V. Tuckson, M.D.

REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Christopher J. DeRespino as chief business officer, effective immediately. In this newly created position, Mr. DeRespino will lead corporate strategy and global business development efforts reporting to Laurent Fischer, M.D., Adverum's chief executive officer.

Adverum Appoints Christopher J. DeRespino as Chief Business Officer

REDWOOD CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the presentation of data from Cohorts 1-4 of the OPTIC Phase 1 clinical trial of ADVM-022 intravitreal (IVT) injection gene therapy in patients requiring frequent anti-VEGF injections for their wet age-related macular degeneration (AMD). These data were previously presented as part of a corporate update on Saturday, November 14, 2020.

Adverum to Present Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in Wet AMD at the Angiogenesis, Exudation, and Degeneration 2021 Virtual Meeting

Adverum Biosciences stock, a clinical stage gene therapy company focused on serious ocular and rare diseases, has rallied by a solid 18% over the last 5 trading days, after the company disclosed in regulatory filings that CEO Laurent Fischer and Chairman Patrick Machado together bought close to.

Can The Gains Continue For Adverum Biosciences After An 18% Move In 5 Days?

Adverum Biotechnologies (ADVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Adverum Biotechnologies (ADVM) Rating Upgrade to Buy

Implied Volatility Surging for Adverum Biotechnologies (ADVM) Stock Options

-- 174,000-square-foot commercial GMP facility in Durham, NC for the manufacturing of ADVM-022, an intravitreal gene therapy in development for wet AMD and DME -- -- Multiple production suites with total capacity of 4000L, with further expansion opportunities --

Adverum Biotechnologies Announces New GMP Gene Therapy Manufacturing Facility

REDWOOD CITY, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the company's presentation at the Piper Sandler 32nd Annual Virtual Healthcare Conference.

Adverum Biotechnologies Presents at the Piper Sandler Annual Virtual Healthcare Conference

-- Maintained efficacy and greatly reduced anti-VEGF treatment burden after  a single IVT injection of ADVM-022 -- -- R obust preliminary aqueous a nti-VEGF protein expression observed at 18 months in Cohort 1 –

Adverum Biotechnologies Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD

Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of 11.43% and -100.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Adverum Biotechnologies (ADVM) Reports Q3 Loss, Misses Revenue Estimates

-- Dr. Carl Regillo to present OPTIC data a t the R etina S ubspecialty D ay on  Friday, November 13, 2020 at 2:15 pm PT -- -- Company to host webcast with key opinion leaders on Saturday , November 14 , 2020 at 7 :30 a m PT --

Adverum Biotechnologies to Present New Data from the OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at AAO 2020 Virtual

Today, we take an in-depth look at Adverum Biotechnologies which has dropped by more than half from highs earlier this year.

Assessing Adverum

REDWOOD CITY, Calif., Sept.  10, 2020  (GLOBE NEWSWIRE) --  Adverum Biotechnologies, Inc.  (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that the company will present at the Cantor Virtual Global Healthcare Conference on Tuesday, September 15, 2020 at 1:00 pm PT.

Adverum Biotechnologies to Participate in the Cantor Virtual Global Healthcare Conference

REDWOOD CITY, Calif., Aug.  18, 2020  (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the closing of its previously announced underwritten public offering of 16,675,000 shares of its common stock at a public offering price of $13.00 per share, which included the full exercise of the underwriters’ option to purchase up to an additional 2,175,000 shares of common stock. The gross proceeds to Adverum before deducting underwriting discounts and commissions and offering expenses payable by Adverum were approximately $216.8 million.

Adverum Biotechnologies Announces Closing of $217 Million Public Offering of Common Stock

Adverum (ADVM) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Adverum (ADVM) Surges: Stock Moves 6.2% Higher

REDWOOD CITY, Calif., Aug.  12, 2020  (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the pricing of its underwritten public offering of 14,500,000 shares of its common stock at a public offering price of $13.00 per share. The company has granted the underwriters a 30-day option to purchase up to an additional 2,175,000 shares of its common stock offered in the public offering at the public offering price, less discounts and commissions. All of the shares in the offering are being sold by Adverum Biotechnologies. Adverum expects gross proceeds from the offering, before deducting the underwriting discounts and commissions and offering expenses, will be approximately $188.5 million, assuming no exercise of the underwriters’ option to purchase additional shares.  The offering is expected to close on or about August 17, 2020, subject to satisfaction of customary closing conditions.

Adverum Biotechnologies Announces Pricing of Public Offering of Common Stock

REDWOOD CITY, Calif., Aug.  11, 2020  (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that it has commenced an underwritten public offering of $200 million of its common stock. The company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. All of the shares in the offering will be sold by Adverum Biotechnologies. The offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Adverum Biotechnologies Announces $200 Million Public Offering of Common Stock

Adverum Biotechnologies, Inc. (ADVM) CEO Laurent Fischer on Q2 2020 Results - Earnings Call Transcript

Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of -20.00% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

News for Adverum Biotechnologies Stock (ADVM)